Great Point Partners LLC cut its stake in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 29.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,263,672 shares of the company's stock after selling 1,378,569 shares during the period. Zura Bio makes up 3.9% of Great Point Partners LLC's investment portfolio, making the stock its 10th biggest holding. Great Point Partners LLC owned 4.86% of Zura Bio worth $13,251,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in ZURA. Renaissance Technologies LLC increased its stake in shares of Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock worth $61,000 after acquiring an additional 5,900 shares during the period. Bank of New York Mellon Corp increased its position in Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company's stock worth $165,000 after purchasing an additional 6,412 shares during the period. Forefront Analytics LLC raised its stake in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock worth $145,000 after buying an additional 7,531 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Zura Bio in the 2nd quarter valued at approximately $43,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Zura Bio in the third quarter valued at approximately $62,000. 61.14% of the stock is owned by institutional investors and hedge funds.
Zura Bio Stock Down 0.3 %
Shares of ZURA stock traded down $0.01 during trading hours on Wednesday, hitting $3.00. The company's stock had a trading volume of 252,387 shares, compared to its average volume of 327,489. The business has a fifty day moving average of $4.12 and a 200-day moving average of $4.03. Zura Bio Limited has a twelve month low of $2.00 and a twelve month high of $6.35.
Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). Equities analysts expect that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.
Insider Activity at Zura Bio
In related news, Director Parvinder Thiara sold 1,001,633 shares of the company's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Someit Sidhu sold 51,728 shares of the business's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares of the company's stock, valued at $8,070,567.66. This trade represents a 2.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 22.10% of the company's stock.
Analysts Set New Price Targets
ZURA has been the subject of several research analyst reports. Leerink Partners assumed coverage on Zura Bio in a research report on Monday, November 4th. They issued an "outperform" rating and a $15.00 price objective for the company. Piper Sandler reiterated an "overweight" rating and issued a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th. Chardan Capital lowered their target price on shares of Zura Bio from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 8th. HC Wainwright reiterated a "neutral" rating and set a $5.00 price target on shares of Zura Bio in a research report on Monday, November 18th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a report on Friday, October 18th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $15.80.
Read Our Latest Report on ZURA
About Zura Bio
(
Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Stories
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
